Samir Rashmikant Patel

CIK: 0001702447

Transaction Breakdown

Open Market Buys (P)4 (17.4%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)3 (13.0%)

Derivative conversions

Awards (A)16 (69.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AKTX

Akari Therapeutics Plc

Director

Discretionary Trading P&L

Holdings

Transaction History (23 total)

AKTX
Akari Therapeutics Plc
Oct 5, 2026
Award(A)
Direct
2.2K shares at avg. $7.90$18K
AKTX
Akari Therapeutics Plc
Aug 18, 2026
Award(A)
Direct
6.3K shares at avg. $7.90$50K
AKTX
Akari Therapeutics Plc
Jul 7, 2026
Exercise(M)
Indirect
5.8K shares at avg. $0.00$2.32
AKTX
Akari Therapeutics Plc
Jul 7, 2026
Exercise(M)
Indirect
1.2K shares at avg. $8.00$10K
AKTX
Akari Therapeutics Plc
Jul 7, 2026
Exercise(M)
Indirect
15.5K shares at avg. $0.00$6.186
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Pre-Funded Warrants to purchase ADRs
Indirect
232K shares at avg. $0.40-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Warrants to purchase American Depositary Shares ("ADRs")
Direct
618.7K shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Pre-Funded Warrants to purchase ADRs
Direct
618.7K shares at avg. $0.40-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Warrants to purchase ADRs
Indirect
232K shares-
AKTX
Akari Therapeutics Plc
Mar 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
225K shares-
AKTX
Akari Therapeutics Plc
Mar 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
175K shares-
AKTX
Akari Therapeutics Plc
Mar 6, 2025
Award(A)
Indirect
406.3K shares at avg. $1.12$455K
AKTX
Akari Therapeutics Plc
Jan 3, 2025
Award(A)
Indirect
208K shares at avg. $0.00$124.8
AKTX
Akari Therapeutics Plc
Dec 27, 2024
Award(A)
Indirect
400K shares at avg. $0.00$200
AKTX
Akari Therapeutics Plc
Dec 26, 2024
Award(A)
Indirect
3.2M shares at avg. $0.00$2K
AKTX
Akari Therapeutics Plc
Dec 24, 2024
Award(A)
Indirect
7.5M shares at avg. $0.00$4K
AKTX
Akari Therapeutics Plc
Dec 23, 2024
Award(A)
Indirect
1.4M shares at avg. $0.00$700
AKTX
Akari Therapeutics Plc
Dec 20, 2024
Award(A)
Indirect
1.4M shares at avg. $0.00$700
AKTX
Akari Therapeutics Plc
Dec 2, 2024
Award(A)
Indirect
419.3M shares at avg. $0.00$503K
AKTX
Akari Therapeutics Plc
Nov 30, 2024
Award(A)
Stock Option (Right to Buy)
Direct
162.6M shares-
AKTX
Akari Therapeutics Plc
Nov 14, 2024
Award(A)
Indirect
1.4B shares-
AKTX
Akari Therapeutics Plc
Oct 31, 2024
Award(A)
Stock Option (Right to Buy)
Direct
79.7M shares-
AKTX
Akari Therapeutics Plc
Sep 30, 2024
Award(A)
Stock Option (Right to Buy)
Direct
175.1M shares-

		Type	Shares	Price		Ownership
Oct 5, 2026	AKTX Akari Therapeutics Plc	Award(A)	2,236	$7.90	$17,662	Direct
Aug 18, 2026	AKTX Akari Therapeutics Plc	Award(A)	6,300	$7.90	$49,764	Direct
Jul 7, 2026	AKTX Akari Therapeutics Plc	Exercise(M)	5,799	$0.00	$2	Indirect
Jul 7, 2026	AKTX Akari Therapeutics Plc	Exercise(M)	1,209	$8.00	$9,672	Indirect
Jul 7, 2026	AKTX Akari Therapeutics Plc	Exercise(M)	15,466	$0.00	$6	Indirect
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Pre-Funded Warrants to purchase ADRs	231,997	$0.40	-	Indirect
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Warrants to purchase American Depositary Shares ("ADRs")	618,658	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Pre-Funded Warrants to purchase ADRs	618,658	$0.40	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Warrants to purchase ADRs	231,997	-	-	Indirect
Mar 20, 2025	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	225,000	-	-	Direct
Mar 20, 2025	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	175,000	-	-	Direct
Mar 6, 2025	AKTX Akari Therapeutics Plc	Award(A)	406,250	$1.12	$455,000	Indirect
Jan 3, 2025	AKTX Akari Therapeutics Plc	Award(A)	208,000	$0.00	$125	Indirect
Dec 27, 2024	AKTX Akari Therapeutics Plc	Award(A)	400,000	$0.00	$200	Indirect
Dec 26, 2024	AKTX Akari Therapeutics Plc	Award(A)	3,200,000	$0.00	$1,600	Indirect
Dec 24, 2024	AKTX Akari Therapeutics Plc	Award(A)	7,500,000	$0.00	$3,750	Indirect
Dec 23, 2024	AKTX Akari Therapeutics Plc	Award(A)	1,400,000	$0.00	$700	Indirect
Dec 20, 2024	AKTX Akari Therapeutics Plc	Award(A)	1,400,000	$0.00	$700	Indirect
Dec 2, 2024	AKTX Akari Therapeutics Plc	Award(A)	419,286,000	$0.00	$503,143	Indirect
Nov 30, 2024	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	162,604,000	-	-	Direct
Nov 14, 2024	AKTX Akari Therapeutics Plc	Award(A)	1,404,622,000	-	$0	Indirect
Oct 31, 2024	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	79,684,000	-	-	Direct
Sep 30, 2024	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	175,080,000	-	-	Direct

1-23 of 23 transactions

About Patel Samir Rashmikant

Patel Samir Rashmikant (SEC CIK 0001702447) files insider reports with the SEC as Director of Akari Therapeutics Plc (AKTX).

Signal8 holds 14 ownership filings by Patel Samir Rashmikant, all Form 4s, filed between Oct 2, 2024 and Oct 16, 2026. Those filings report 23 transactions, from Sep 30, 2024 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Patel Samir Rashmikant's filings is in TAMPA, FL.

Recent filings by Patel Samir Rashmikant

Oct 5, 2026: Grant or award of AKTX shares (Form 4, code A).
Aug 18, 2026: Grant or award of AKTX shares (Form 4, code A).
Jul 7, 2026: Option exercises of AKTX shares (3 lines, Form 4, code M).
Dec 16, 2025: Open-market purchases of AKTX derivative securities (4 lines, Form 4, code P).
Mar 20, 2025: Grants or awards of AKTX derivative securities (2 lines, Form 4, code A).

Other insiders filing for Akari Therapeutics Plc (AKTX)

Prudo-Chlebosz Raymond, Director
Huh Hoyoung, Director
Patel Sandip I, Director
Bazemore Robert B, Director
Gaslightwala Abizer, CEO
Vat-Ho Vatnak, Chief Business Officer

How to read Form 4 transaction codes